Latest Insider Transactions at Entrada Therapeutics, Inc. (TRDA)
This section provides a real-time view of insider transactions for Entrada Therapeutics, Inc. (TRDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Entrada Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Entrada Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,800
-0.53%
|
$27,000
$15.0 P/Share
|
|
May 14
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
25,000
+21.29%
|
$350,000
$14.59 P/Share
|
|
May 09
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,200
+3.16%
|
$30,800
$14.25 P/Share
|
|
May 08
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,276
+3.37%
|
$31,864
$14.04 P/Share
|
|
Apr 08
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,600
+3.97%
|
$33,800
$13.57 P/Share
|
|
Mar 28
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
1,512
+2.44%
|
$19,656
$13.75 P/Share
|
|
Mar 26
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,750
+4.47%
|
$35,750
$13.64 P/Share
|
|
Mar 25
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
3,180
+5.37%
|
$41,340
$13.36 P/Share
|
|
Mar 22
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
3,118
+5.57%
|
$40,534
$13.76 P/Share
|
|
Mar 21
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
704
+1.39%
|
$9,152
$13.24 P/Share
|
|
Mar 20
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
1,128
+2.25%
|
$13,536
$12.66 P/Share
|
|
Mar 19
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
900
+1.84%
|
$10,800
$12.66 P/Share
|
|
Mar 15
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+9.76%
|
$18,000
$2.1 P/Share
|
|
Mar 06
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,086
-5.22%
|
$49,032
$12.31 P/Share
|
|
Mar 06
2024
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
1,826
-1.31%
|
$21,912
$12.32 P/Share
|
|
Mar 05
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,505
-0.71%
|
$18,060
$12.28 P/Share
|
|
Mar 05
2024
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,486
-1.06%
|
$17,832
$12.28 P/Share
|
|
Mar 05
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,471
-1.85%
|
$17,652
$12.28 P/Share
|
|
Mar 05
2024
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,049
-1.46%
|
$60,588
$12.28 P/Share
|
|
Mar 04
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
761
-0.18%
|
$9,132
$12.9 P/Share
|
|
Mar 04
2024
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-0.27%
|
$9,024
$12.9 P/Share
|
|
Mar 04
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
744
-0.46%
|
$8,928
$12.9 P/Share
|
|
Mar 04
2024
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,555
-0.37%
|
$30,660
$12.9 P/Share
|
|
Mar 01
2024
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
44,100
+17.27%
|
-
|
|
Mar 01
2024
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
93,100
+29.38%
|
-
|
|
Mar 01
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,900
+27.75%
|
-
|
|
Mar 01
2024
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
104,700
+23.13%
|
-
|
|
Feb 15
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.41%
|
$15,000
$15.0 P/Share
|
|
Jan 16
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.41%
|
$15,000
$15.99 P/Share
|
|
Dec 26
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
94
-0.19%
|
$1,504
$16.67 P/Share
|
|
Dec 26
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
94
+0.19%
|
$188
$2.1 P/Share
|
|
Dec 22
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,206
-8.91%
|
$153,090
$15.86 P/Share
|
|
Dec 22
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,206
+14.58%
|
$20,412
$2.1 P/Share
|
|
Dec 21
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,200
-4.25%
|
$33,000
$15.07 P/Share
|
|
Dec 21
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+4.08%
|
$4,400
$2.1 P/Share
|
|
Dec 20
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.41%
|
$15,000
$15.0 P/Share
|
|
Nov 13
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.4%
|
$16,000
$16.23 P/Share
|
|
Oct 17
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.4%
|
$15,000
$15.0 P/Share
|
|
Sep 13
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.4%
|
$15,000
$15.0 P/Share
|
|
Sep 06
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
950
-0.94%
|
$12,350
$13.74 P/Share
|
|
Sep 06
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
972
-0.99%
|
$12,636
$13.72 P/Share
|
|
Sep 06
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
892
-1.09%
|
$11,596
$13.73 P/Share
|
|
Sep 05
2023
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
449
-0.27%
|
$6,286
$14.46 P/Share
|
|
Sep 05
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
426
-0.84%
|
$5,964
$14.46 P/Share
|
|
Sep 05
2023
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,440
-0.57%
|
$20,160
$14.46 P/Share
|
|
Sep 05
2023
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
436
-0.88%
|
$6,104
$14.46 P/Share
|
|
Sep 05
2023
|
Nerissa Kreher Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
401
-0.97%
|
$5,614
$14.46 P/Share
|
|
Sep 01
2023
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
14,200
+7.81%
|
-
|
|
Sep 01
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,200
+21.8%
|
-
|
|
Sep 01
2023
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
49,650
+16.53%
|
-
|